ABCSG 62 / CAMBRIA-2 Overview

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.

Start: (global): 10/2023; FPI 10/2023
(national): 04/2024
Coordinating Investigator AT: Daniel Egle, Innsbruck
Sample: 5500 (global),
144 (national)
Study design:
(Click to enlarge)

Share on